CAPSUGEL Announces License Agreement With Teijin Pharma to Offer Vcaps(R) HPMC Capsules for Dry Powder Inhalation
Published: Oct 08, 2007
PEAPACK, NJ--(Marketwire - October 08, 2007) - Capsugel, the leading global provider of dosage form solutions, has announced it will offer its Vcaps® HPMC (hypromellose) capsules for use in dry powder inhalation (DPI) products worldwide. The announcement follows the successful conclusion of a license agreement between Capsugel and Teijin Pharma Limited, part of the Teijin Group of Japan. The agreement grants Capsugel a license to Teijin's entire patent portfolio related to the use of HPMC capsules for inhalation products.